EMEA-000366-PIP05-12-M02

Key facts

Invented name
Humira
Active substance
adalimumab
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0200/2016
PIP number
EMEA-000366-PIP05-12-M02
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of non-infectious uveitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
AbbVie Limited

E-mail: paediatricteam@abbvie.com
Tel. +44 (0)7919881614

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000366-PIP05-12-M02
Compliance opinion date
14/10/2016
Compliance outcome
positive

Decision

How useful was this page?

Add your rating